fda peptide warning letters september 2025 Warning letters - HimsFDA peptides FDA Peptide Warning Letters September 2025: A Comprehensive Overview of Regulatory Actions

RetatrutideFDAapproval date The FDA has intensified its scrutiny of the peptide market, issuing a significant wave of warning letters in September 20252025年9月17日—OnTuesday, September 16, 2025,FDAposted 40 Untitled Letters and 8Warning Lettersdirected at prescription drug and biologic Sponsors' .... These actions target companies engaged in the compounding and marketing of peptides, particularly those related to GLP-1 agonists and weight loss drugs. This proactive stance reflects the FDA's commitment to ensuring the safety and efficacy of pharmaceutical products available to the public.

A notable surge in enforcement activity occurred around September 9, 2025, with numerous companies receiving warning letters. These letters serve as official notifications of regulatory violations. For instance, companies like Healthy Male, Slendid, and JulyMD were among those receiving a WARNING LETTER. September 9, 2025, detailing specific compliance issues. The FDA has been particularly focused on preventing the marketing of compounded GLP-1s as generic alternatives without proper regulatory oversight.

The enforcement actions extend to major pharmaceutical players as well. Eli Lilly and Company has been a recipient of FDA warning letters, with at least three such letters issued concerning their glucagon-likepeptide-1 receptor agonist (GLP-1RA) tirzepatide, known by its US brand name2025年10月7日—On September 9, 2025, the agency significantly increased its enforcement activity by issuingmore than 40 warning lettersto telehealth-based .... One such An FDA warning letter sent to Eli Lilly and Company (Lilly) on Sept. 9, 2025 was made public, highlighting concerns over direct-to-consumer programs. The FDA has also cautioned against the coadministration of tirzepatide with other GLP-1 receptor agonists or peptide-containing products.

The FDA's crackdown in September 2025 encompasses various deceptive advertising practices. The agency issued more than 40 warning letters to telehealth-based companies and others for misleading advertisements related to compounded weight loss drugsSlendid September 09, 2025. This initiative, which saw a significant increase in enforcement activity, was further underscored by the FDA posting 40 Untitled Letters and 8 Warning Letters on Tuesday, September 16, 2025, directed at prescription drug and biologic sponsors.2026年1月21日—Among these were 58Warning Lettersissued onSeptember9 to challenge the advertising of compounded GLP-1 agonists and erectile dysfunction ... The FDA also disclosed warning letters for dozens of drug companies following a September 9, 2025, announcement regarding misleading ads. Reports indicate that in FY2025, CDER Warning Letters jumped by 50%, with the FDA issuing 126 import alertsThe US Food and Drug Administration (FDA) issued a flurry oflettersto manufacturers in early.September 2025following a presidential ....

Beyond domestic oversight, the FDA is also addressing the influx of potentially dangerous drugs from illegal foreign sources. The agency established a “green list” import alert on September 05, 2025, to help prevent the entry of such products.作者：MA Makary·2025·被引用次数：6—TheFDAhas initiated enforcement action, delivering approximately 100 cease-and-desistletterstargeting the most severe regulatory violations. In addition, we ... The availability of compounded versions of GLP-1s has surged in the U.S., despite prior warnings from the FDA about knockoff weight loss drugs.

The FDA's concerns extend to unapproved GLP-1 drugs being used for unindicated purposes. The agency has warned companies illegally selling unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeled for researchSlendid September 09, 2025. This includes issuing multiple warning letters to online semaglutide suppliers that sold unapproved and/or misbranded drugs.

The FDA's aggressive stance signals a period of heightened regulatory oversight for companies operating in the peptide and compounded drug space. The FDA has signaled an aggressive stance, issuing warning letters and guidance to compounding pharmacies violating regulations regarding these peptides. The agency used to send more than a hundred warning letters, and the actions in September 2025 indicate a renewed focus on this area. The FDA's actions in September 2025 demonstrate a clear intent to combat deceptive drug advertising and ensure that pharmaceutical products meet stringent safety and quality standards. The FDA also released around 80 warning letters following a September 9, 2025, presidential memorandum, setting forth the direction for these enforcement activities.